The many alternatives to hydroquinone make this an exciting time for using cosmeceuticals to treat pigmentary disorders, according to Dr. Heather Woolery-Lloyd, director of the Skin of Color Division at the University of Miami Miller School of Medicine’s Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery. In an interview with Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium, Dr. Woolery-Lloyd outlines older and newer cosmeceutical ingredients. Watch as she details how she incorporates cosmeceuticals into a patient’s skincare routine. Think sunscreen isn’t a cosmeceutical? Hear what Dr. Woolery-Lloyd thinks.
Further Reading
If you want to read more about cosmeceuticals for treating pigmentary disorders, check out the following articles published in the Journal of Drugs in Dermatology:
ABSTRACT
Hyperpigmentation, uneven skin tone, textural changes, and dull skin are common cosmetic concerns in skin of color. Other signs of aging, including fine lines, deeper wrinkles, and skin laxity, also occur but may present in later decades. In-office procedures such as laser treatments, energy devices, toxins, fillers, and chemical peels are useful options for addressing the most common cosmetic concerns in skin of color patients. Skincare can play an important role in improving cosmetic outcomes when used in conjunction with in-office procedures. With the availability of these approaches, clinicians can now integrate in-office procedures with skincare strategies to offer patients with skin of color a comprehensive treatment plan that meets their needs.
ABSTRACT
Background: Melasma is a chronic pigmentary disorder. In this study, an innovative cream combining cysteamine and tranexamic acid (TXA) was assessed.
Objective: To evaluate the safety, efficacy, and patient satisfaction of a novel nano-formulated cysteamine and TXA combination cream in treating subjects with epidermal melasma.
Methods: Fifty (50) randomized subjects participated and received cysteamine and TXA combination cream. The cream was applied for 30 minutes daily for a 3-month duration. Treatment effectiveness, safety, patient satisfaction, and adherence were evaluated.
Results: A continuous improvement in melasma was observed, with modified Melasma Area and Severity Index (mMASI) scores improving by 40%, 57%, and 63% at 30, 60, and 90 days, respectively. The primary endpoint of a decrease in mMASI scores was met, with 91% of participants experiencing melasma improvement. Patient Satisfaction and Patient Adherence scores indicated satisfaction. Convenience exhibited the strongest correlation with patient adherence.
Conclusion: Nano-formulated cysteamine and TXA combination cream showed significant efficacy in decreasing mMASI score while demonstrating a strong safety profile and patient satisfaction.
Did you enjoy this video interview? Find more here.
